A Study of LY3457263 in Obese Participants
Completed · Phase 1 · Has a placebo group
Conditions studied: Overweight, Obesity
In brief
The main purpose of this study is to evaluate the safety and tolerability of LY3457263 when administered in combination with tirzepatitide in overweight or obese participants. The study will also evaluate how much of LY3457263 gets into the blood stream and how long it takes the body to remove it in overweight or obese participants. The study will last up to approximately 11 weeks.
Key facts
- Study ID
- NCT05582096
- Run by
- Eli Lilly and Company
- People needed
- 38
- Starts
- 2022-11-11
- Expected to finish
- 2023-06-08
- Last updated by the study team
- 2023-07-18
Who can join
Age: 20 and older, up to 70. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Participants who are overtly healthy as determined by medical evaluation
- Have a stable body weight and body mass index (BMI) within the range 27.0 to 45.0 kilograms per meter squared (kg/m²)
- Male or female participants not of childbearing potential
You may not qualify if…
- Have a mean sitting systolic blood pressure (BP) higher than 160 millimeters of mercury (mmHg) or a mean sitting diastolic BP higher than 90 mmHg from 3 measurements
- Have an abnormal 12-lead electrocardiogram (ECG) at screening
- Have type 1 or type 2 diabetes mellitus
Where it is running
- LabCorp CRU, Inc. — Daytona Beach, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.